Literature DB >> 20633309

Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients.

Roosmarijn C Drexhage1, Leonie van der Heul-Nieuwenhuijsen, Roos C Padmos, Nico van Beveren, Dan Cohen, Marjan A Versnel, Willem A Nolen, Hemmo A Drexhage.   

Abstract

Accumulating evidence indicates an activated inflammatory response system as a vulnerability factor for schizophrenia (SZ) and bipolar disorder (BD). We aimed to detect a specific inflammatory monocyte gene expression signature in SZ and compare such signature with our recently described inflammatory monocyte gene signature in BD. A quantitative-polymerase chain reaction (Q-PCR) case-control gene expression study was performed on monocytes of 27 SZ patients and compared to outcomes collected in 56 BD patients (all patients naturalistically treated). For Q-PCR we used nine 'SZ specific genes' (found in whole genome analysis), the 19 BD signature genes (previously found by us) and six recently described autoimmune diabetes inflammatory monocyte genes. Monocytes of SZ patients had (similar to those of BD patients) a high inflammatory set point composed of three subsets of strongly correlating genes characterized by different sets of transcription/MAPK regulating factors. Subset 1A, characterized by ATF3 and DUSP2, and subset 1B, characterized by EGR3 and MXD1, were shared between BD and SZ patients (up-regulated in 67% and 51%, and 34% and 41%, respectively). Subset 2, characterized by PTPN7 and NAB2 was up-regulated in the monocytes of 62% BD, but down-regulated in the monocytes of 48% of SZ patients. Our approach shows that monocytes of SZ and BD patients overlap, but also differ in inflammatory gene expression. Our approach opens new avenues for nosological classifications of psychoses based on the inflammatory state of patients, enabling selection of those patients who might benefit from an anti-inflammatory treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20633309     DOI: 10.1017/S1461145710000799

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  43 in total

1.  A Study of TNF Pathway Activation in Schizophrenia and Bipolar Disorder in Plasma and Brain Tissue.

Authors:  Eva Zsuzsanna Hoseth; Thor Ueland; Ingrid Dieset; Rebecca Birnbaum; Joo Heon Shin; Joel Edward Kleinman; Thomas Michael Hyde; Ragni Helene Mørch; Sigrun Hope; Tove Lekva; Aurelija Judita Abraityte; Annika E Michelsen; Ingrid Melle; Lars Tjelta Westlye; Torill Ueland; Srdjan Djurovic; Pål Aukrust; Daniel R Weinberger; Ole Andreas Andreassen
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

2.  Impaired monocyte activation in schizophrenia: ultrastructural abnormalities and increased IL-1β production.

Authors:  Natalya A Uranova; P D Bonartsev; L V Androsova; V I Rakhmanova; V G Kaleda
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-03-17       Impact factor: 5.270

3.  Proinflammatory cytokines and their membrane-bound receptors are altered in the lymphocytes of schizophrenia patients.

Authors:  Ghanshyam N Pandey; Xinguo Ren; Hooriyah S Rizavi; Hui Zhang
Journal:  Schizophr Res       Date:  2015-03-04       Impact factor: 4.939

4.  Genetic variation in the exome: Associations with alcohol and tobacco co-use.

Authors:  Jacqueline M Otto; Ian R Gizer; Jarrod M Ellingson; Kirk C Wilhelmsen
Journal:  Psychol Addict Behav       Date:  2017-04-03

5.  C4A mRNA expression in PBMCs predicts the presence and severity of delusions in schizophrenia and bipolar disorder with psychosis.

Authors:  Jennifer K Melbourne; Cherise Rosen; Benjamin Feiner; Rajiv P Sharma
Journal:  Schizophr Res       Date:  2018-02-12       Impact factor: 4.939

6.  Transcriptomic abnormalities in peripheral blood in bipolar disorder, and discrimination of the major psychoses.

Authors:  Jonathan L Hess; Daniel S Tylee; Rahul Barve; Simone de Jong; Roel A Ophoff; Nishantha Kumarasinghe; Paul Tooney; Ulrich Schall; Erin Gardiner; Natalie Jane Beveridge; Rodney J Scott; Surangi Yasawardene; Antionette Perera; Jayan Mendis; Vaughan Carr; Brian Kelly; Murray Cairns; Ming T Tsuang; Stephen J Glatt
Journal:  Schizophr Res       Date:  2019-08-04       Impact factor: 4.939

7.  Levels of Red Blood Cell Fatty Acids in Patients With Psychosis, Their Unaffected Siblings, and Healthy Controls.

Authors:  Suzanne Medema; Roel J T Mocking; Maarten W J Koeter; Frédéric M Vaz; Carin Meijer; Lieuwe de Haan; Nico J M van Beveren; René Kahn; Lieuwe de Haan; Jim van Os; Durk Wiersma; Richard Bruggeman; Wiepke Cahn; Carin Meijer; Inez Myin-Germeys
Journal:  Schizophr Bull       Date:  2015-09-18       Impact factor: 9.306

8.  Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects.

Authors:  Brian J Miller; Bintou Gassama; Dale Sebastian; Peter Buckley; Andrew Mellor
Journal:  Biol Psychiatry       Date:  2012-10-11       Impact factor: 13.382

9.  Pro-/anti-inflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis of schizophrenia.

Authors:  Borja García-Bueno; Miquel Bioque; Karina S Mac-Dowell; M Fe Barcones; Monica Martínez-Cengotitabengoa; Laura Pina-Camacho; Roberto Rodríguez-Jiménez; Pilar A Sáiz; Carmen Castro; Amalia Lafuente; Javier Santabárbara; Ana González-Pinto; Mara Parellada; Gabriel Rubio; M Paz García-Portilla; Juan A Micó; Miguel Bernardo; Juan C Leza
Journal:  Schizophr Bull       Date:  2013-03-13       Impact factor: 9.306

Review 10.  Towards an Immunophenotype of Schizophrenia: Progress, Potential Mechanisms, and Future Directions.

Authors:  Brian J Miller; David R Goldsmith
Journal:  Neuropsychopharmacology       Date:  2016-09-22       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.